Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27332458 | 1.00 | P2RX7 (0.36) | P2RX7NR1H2NR1H3FFAR1MAOA | |
| SCHEMBL27333086 | 0.88 | P2RX7 (0.37) | P2RX7NR1H2NR1H3FGFR4 | |
| SCHEMBL27331560 | 0.82 | NR1H2 (0.36) | NR1H2NR1H3FFAR1MAOAMAOB | |
| SCHEMBL30723622 | 0.82 | NR1H2 (0.36) | NR1H2NR1H3FFAR1MAOAMAOB | |
| SCHEMBL30723682 | 0.81 | NOTUM (0.42) | P2RX7NR1H2NR1H3 | |
| SCHEMBL27332105 | 0.80 | CYP3A4 (0.36) | NR1H2NR1H3MAOAMAOBMRGPRX4 | |
| SCHEMBL27331561 | 0.77 | NR1H2 (0.33) | NR1H2NR1H3 | |
| SCHEMBL30723698 | 0.76 | ALKBH1 (0.37) | NR1H2NR1H3FGFR4 | |
| SCHEMBL27331573 | 0.76 | ALKBH1 (0.37) | NR1H2NR1H3FGFR4 | |
| SCHEMBL30723652 | 0.76 | ALKBH1 (0.44) | P2RX7FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4532487-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | Sanofi US Services Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119301115-A | Compounds for enhancing read-through of genes containing premature stop codons and methods of making and using the same | 赛诺菲美国服务公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023235384-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | SANOFI US SERVICES INC. (US) | 2023-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228865-A1 | COMPOUNDS FOR ENHANCING READ THROUGH OF GENES CONTAINING PREMATURE TERMINATION CODONS AND METHODS FOR MAKING AND USING THE SAME | UPF1, NUDT21, RNGTT | P2RX7 3543/4885NR1H2 3787/4885NR1H3 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.